Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Lymphoma

  Free Subscription


17.06.2024

1 Am J Hematol
1 Am J Surg Pathol
1 Blood
1 BMC Cancer
1 Bone Marrow Transplant
3 Br J Haematol
1 Cancer Lett
1 Eur J Haematol
3 Haematologica
2 Int J Radiat Oncol Biol Phys
1 J Virol
2 Leuk Lymphoma
3 N Engl J Med


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. ABABNEH HS, Ng AK, Frigault MJ, Jacobson CA, et al
    Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
    Am J Hematol. 2024 Jun 11. doi: 10.1002/ajh.27409.
    PubMed        


    Am J Surg Pathol

  2. IVANOVA VS, Menter T, Zaino J, Mertz KD, et al
    The Genetic Landscape of Primary Breast Marginal Zone Lymphoma Identifies a Mutational-driven Disease With Similarities to Ocular Adnexal Lymphoma.
    Am J Surg Pathol. 2024 Jun 12. doi: 10.1097/PAS.0000000000002257.
    PubMed         Abstract available


    Blood

  3. CHRISMAN LP, Trimark PF, Pang Y, Pease DR, et al
    Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify Sezary syndrome patients with low blood burden.
    Blood. 2024 Jun 7:blood.2023023584. doi: 10.1182/blood.2023023584.
    PubMed         Abstract available


    BMC Cancer

  4. SAATCI D, Zhu C, Harnden A, Hippisley-Cox J, et al
    Presentation of B-cell lymphoma in childhood and adolescence: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:718.
    PubMed         Abstract available


    Bone Marrow Transplant

  5. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    PubMed         Abstract available


    Br J Haematol

  6. LIM YJ, Ward V, Brown A, Phillips E, et al
    Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
    Br J Haematol. 2024 Jun 13. doi: 10.1111/bjh.19562.
    PubMed         Abstract available

  7. ROSSETTI S, Juul SJ, Eriksson F, Warming PE, et al
    Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study.
    Br J Haematol. 2024 Jun 12. doi: 10.1111/bjh.19586.
    PubMed         Abstract available

  8. SCIARRA R, Merli M, Cristinelli C, Lucioni M, et al
    Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
    Br J Haematol. 2024;204:2242-2253.
    PubMed         Abstract available


    Cancer Lett

  9. LI B, Adam Eichhorn PJ, Chng WJ
    Targeting the ubiquitin pathway in lymphoid malignancies.
    Cancer Lett. 2024;594:216978.
    PubMed         Abstract available


    Eur J Haematol

  10. KURTE MS, Siefen AC, Jakobs F, Poos T, et al
    Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
    Eur J Haematol. 2024 Jun 10. doi: 10.1111/ejh.14248.
    PubMed         Abstract available


    Haematologica

  11. IZUMIYAMA K, Inao T, Goto H, Harada S, et al
    Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284841.
    PubMed         Abstract available

  12. CHENG J, Xi L, Jang Y, Kim J, et al
    An investigation of germline variants of HAVCR2 in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284738.
    PubMed         Abstract available

  13. KAPHAN E, Bettega F, Vallet N, Fegueux N, et al
    PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2024.284968.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  14. MCCAMMACK E, Terezakis S
    Extirpation in Nodal DLBCL: What and Where Is the Relapse Risk?
    Int J Radiat Oncol Biol Phys. 2024;119:718.
    PubMed        

  15. MCMULLEN KP, Sawyer J
    Resected Diffuse Large B Cell Lymphoma: Does Extirpation Mean No Irradiation in the PET-Response Based Milieu?
    Int J Radiat Oncol Biol Phys. 2024;119:716-717.
    PubMed        


    J Virol

  16. ZHANG Y, Dong Z, Gu F, Xu Y, et al
    Degradation of TRIM32 is induced by RTA for Kaposi's sarcoma-associated herpesvirus lytic replication.
    J Virol. 2024;98:e0000524.
    PubMed         Abstract available


    Leuk Lymphoma

  17. HONG D, Yin M, Li J, Deng Z, et al
    Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study.
    Leuk Lymphoma. 2024 Jun 11:1-11. doi: 10.1080/10428194.2024.2364830.
    PubMed         Abstract available

  18. CHANG JE, Wang T, Kim K, Folstad M, et al
    Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
    PubMed         Abstract available


    N Engl J Med

  19. VELEANU L, Lamant L, Sibon D
    Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.
    N Engl J Med. 2024;390:2129-2130.
    PubMed        

  20. OZDEMIRLI M, Loughney TM, Deniz E, Chahine JJ, et al
    Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.
    N Engl J Med. 2024;390:2074-2082.
    PubMed         Abstract available

  21. HAMILTON MP, Sugio T, Noordenbos T, Shi S, et al
    Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
    N Engl J Med. 2024;390:2047-2060.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.